CORDIS
EU research results

CORDIS

English EN
Accelerated Early staGe drug diScovery

Accelerated Early staGe drug diScovery

Objective

The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia.
The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation.
The consortium joins leading academic and industry researchers in an open innovation environment for innovative drug development in Europe. It is supported by several additional partners and stakeholders in the field. Integrated training of the fellows takes place at the host institute and by secondments, research schools and individual training within the AEGIS network. The scientific training includes complementary skills, management, intellectual property rights, fund raising, communication and career planning. AEGIS will improve the availability of a highly skilled workforce for European industries and research, greatly enhance the employability and the career perspectives of young researchers for academia as well as for industry, and will be the seed of a sustainable development in innovative drug discovery, in particular for rare and neglected diseases.

Coordinator

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Address

Ingolstadter Landstrasse 1
85764 Neuherberg

Germany

Activity type

Research Organisations

EU Contribution

€ 498 432,96

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

PHILIPPS UNIVERSITAET MARBURG

Germany

EU Contribution

€ 498 432,96

RIJKSUNIVERSITEIT GRONINGEN

Netherlands

EU Contribution

€ 510 748,56

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 263 659,32

INSTITUT PASTEUR

France

EU Contribution

€ 525 751,20

UNIWERSYTET JAGIELLONSKI

Poland

EU Contribution

€ 224 137,44

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 265 226,76

NOVARTIS PHARMA AG

Switzerland

EU Contribution

€ 265 226,76

RIDGEVIEW INSTRUMENTS AB

Sweden

EU Contribution

€ 263 659,32

ASTRAZENECA AB

Sweden

EU Contribution

€ 263 659,32

GIOTTO BIOTECH SRL

Italy

EU Contribution

€ 258 061,32

Partners (15)

Sort alphabetically

Expand all

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

UNIVERSITY OF PITTSBURGH

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

TECHNISCHE UNIVERSITAET MUENCHEN

ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE

Astex

UNIWERSYTET JAGIELLONSKI

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION

UNTERNEHMERTUM GMBH

Patentanwalt Dietmar Forstmeyer

UNIVERSITA DEGLI STUDI DI FIRENZE

RUHR-UNIVERSITAET BOCHUM

TECHNISCHE UNIVERSITEIT EINDHOVEN

TelesisPharma

Project information

Grant agreement ID: 675555

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 836 995,92

  • EU contribution

    € 3 836 995,92

Coordinated by:

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany